Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of AMG 193 in previously treated MTAP-deleted advanced non-small cell lung cancer
CTR20244395Phase 2Terminated
- Sponsor
- Amgen
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anvumetostat in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoints: Objective response, Safety events and 2 more. Started Apr 2025; status: terminated.
02
Drugs
anvumetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244395.